Plasma homocysteine levels in renal transplant patients on tacrolimus therapy

Abstract

Increased plasma total homocysteine levels afford an independent risk factor to assess cardiovascular morbidity in patients with normal and impaired renal function, including stable transplant recipients. The purpose of this study was to evaluate plasma homocysteine levels and factors known to influence homocysteine metabolism (folate and Vitamin B12) in renal transplanted patients treated with tacrolimus. Plasma homocysteine, serum folate and serum vitamin B12 concentrations were measured in 18 cadaveric renal transplant patients with stable function both before and 3 months after the renal transplantation. While the mean plasma homocysteine level in the renal transplant group was significantly higher than in the control group, no significant change was observed following renal transplantation under tacrolimus therapy (16.84 ± 6.43 μmol/L vs 16.02 ± 6.54 μmol/L). The levels of folate before and after transplantation were considerably lower than the control group; a significant effect of tacrolimus has not been observed (7.32 ± 4.68 ng/mL and 7.55 ± 5.20 ng/mL). Serum vitamin B12 levels in the transplant group were significantly lower than the control group; a significant decline was seen 3 months after the renal transplantation (448.94 ± 230.03 pg/mL vs 334.38 ± 240.61 pg/mL).Consequently, although plasma homocysteine levels of renal transplant recipients are higher, a lowering effect of tacrolimus therapy was not observed on plasma homocysteine levels. The lower levels of folate and Vitamin B12 in the transplant group compared to a control group supports therapy with folate and Vitamin B12 to decrease homocysteine concentrations.